Rectal Artery Infusion Chemotherapy Combined With Anti-PD1 Antibody for MSS LARC (RAIC)

  • End date
    Apr 25, 2025
  • participants needed
  • sponsor
    Second Affiliated Hospital, School of Medicine, Zhejiang University
Updated on 14 May 2022
monoclonal antibodies
abdominoperineal resection
total mesorectal excision


The purpose of this study is to explore whether rectal artery infusion chemotherapy combined with anti-PD1 antibody is an effective neoadjuvant therapy for the microsatellite stable locally advanced rectal cancer.


Neoadjuvant chemoradiation is the standard treatment for locally advanced rectal cancer. Neoadjuvant chemoradiotherapy can achieve a pathological complete response rate (pCR) of about 20%. However, radiotherapy can cause tissue edema and fibrosis, increasing the risk of anastomotic leakage, resulting in rectal, urinary, and sexual dysfunction. Neoadjuvant chemotherapy or immunotherapy can avoid these adverse reactions, but the pCR rate of chemotherapy is significantly lower than that of neoadjuvant radiotherapy, and immunotherapy is less effective for MSS patients with weak immunogenicity. This study is a prospective, single-arm, single-center trial. The study will enhance the local killing effect of oxaliplatin through rectal artery infusion and induce immunogenic cell death (ICD) to enhance tumor antigen presentation, and then combine anti-PD1 antibody for neoadjuvant therapy. The study will address whether this treatment combination achieves pCR rates that are non-inferior to neoadjuvant RT for MSS-type locally advanced rectal cancer. It is known that the effective rate of oxaliplatin-containing intravenous chemotherapy for colorectal cancer is about 60%. In this study, 2 cycles of XELOX induction chemotherapy were firstly performed to screen out patients who were sensitive to chemotherapy. These patients were then infused with oxaliplatin via the superior rectal artery and oral capecitabine, combined with anti-PD1 antibody therapy for 2 cycles, and then underwent TME surgery. The primary endpoint of the study was the pCR rate.

Condition Rectal Neoplasms
Treatment Capecitabine, Oxaliplatin, Anti-PD-1 monoclonal antibody, Rectectomy
Clinical Study IdentifierNCT05307198
SponsorSecond Affiliated Hospital, School of Medicine, Zhejiang University
Last Modified on14 May 2022


Yes No Not Sure

Inclusion Criteria

Pathologically diagnosed rectal adenocarcinoma
Age ≥18 years old and ≤75 years old
MRI stage T3/4 and or N+, and no distant metastasis
Life expectancy of 1 year The above
Informed consent, no contraindications to chemotherapy exist
The distance from the lower edge of the tumor to the anus is less than or equal to 12cm by MRI

Exclusion Criteria

Refused to participate in this study
Multifocal colorectal cancer
Past history of malignant tumors, except for basal cell carcinoma/papillary thyroid carcinoma/various types of carcinoma in situ
Unable to receive chemotherapy , such as but not limited to bone marrow suppression, etc
Major organ diseases (such as but not limited to COPD, coronary heart disease and renal insufficiency, etc.) acute attack and or severe acute infectious diseases (such as but not limited to hepatitis, pneumonia and myocarditis, etc.), ASA score> 3
Mental disorder or illiteracy or language and communication barriers cannot understand the research plan
There are contraindications to arterial puncture, such as but not limited to severe arteriosclerosis or even atresia, coagulation dysfunction, long-term use of anticoagulant drugs and cannot be stopped, etc
Rectal tumor has obstruction or high risk of obstruction and or there is bleeding and/or perforation
Peripheral sensory nerve disorder, unable to receive oxaliplatin chemotherapy
Lateral pelvic lymph node metastasis (mainly supplied by internal iliac artery)
Pregnancy or breastfeeding
Unable to accept MRI examination
Consecutive use of glucocorticoids for more than 3 days within 1 month before signing the consent form
Tumor directly invades or adheres to adjacent organs、structures(T4b) or tumor invaded MRF(Mesoretal Fascia)
Other scenarios deemed inappropriate by the investigators
Clear my responses

How to participate?

Step 1 Connect with a study center
What happens next?
  • You can expect the study team to contact you via email or phone in the next few days.
  • Sign up as volunteer  to help accelerate the development of new treatments and to get notified about similar trials.

You are contacting

Investigator Avatar

Primary Contact


Additional screening procedures may be conducted by the study team before you can be confirmed eligible to participate.

Learn more

If you are confirmed eligible after full screening, you will be required to understand and sign the informed consent if you decide to enroll in the study. Once enrolled you may be asked to make scheduled visits over a period of time.

Learn more

Complete your scheduled study participation activities and then you are done. You may receive summary of study results if provided by the sponsor.

Learn more

Similar trials to consider


Browse trials for

Not finding what you're looking for?

Every year hundreds of thousands of volunteers step forward to participate in research. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.

Sign up as volunteer

user name

Added by • 



Reply by • Private

Lorem ipsum dolor sit amet consectetur, adipisicing elit. Ipsa vel nobis alias. Quae eveniet velit voluptate quo doloribus maxime et dicta in sequi, corporis quod. Ea, dolor eius? Dolore, vel!

  The passcode will expire in None.

No annotations made yet

Add a private note
  • abc Select a piece of text from the left.
  • Add notes visible only to you.
  • Send it to people through a passcode protected link.
Add a private note